Download presentation
Presentation is loading. Please wait.
Published byΠαμφιλος Παπαδάκης Modified over 5 years ago
1
Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma
Walid K. Abu Saleh, MD, Basel Ramlawi, MD, Oz M. Shapira, MD, Odeaa Al Jabbari, MD, Vinod Ravi, MD, Robert Benjamin, MD, Jean- Bernard Durand, MD, Monika J. Leja, MD, Shanda H. Blackmon, MD, Brian A. Bruckner, MD, Michael J. Reardon, MD The Annals of Thoracic Surgery Volume 104, Issue 1, Pages (July 2017) DOI: /j.athoracsur Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 Proposed management algorithm for neoadjuvant therapy of cardiac sarcomas. The Annals of Thoracic Surgery , 90-96DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Median cumulative (Cum) survival of patients who received neoadjuvant chemotherapy (20 months) was double that of patients who did not (9.5 months, p = 0.417). Blue line indicates neoadjuvant chemotherapy; green line indicates no chemotherapy; blue hatchmarks indicate chemotherapy censored data; green hatchmarks indicate no-chemotherapy censored data. The Annals of Thoracic Surgery , 90-96DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 Patients with negative surgical margins (R0 resection) had a significantly longer median cumulative (Cum) overall survival (53.5 months) than patients who had positive margins (9.5 months, p = 0.004). Blue line indicates negative margins; green line indicates positive margins; blue hatchmarks indicate negative-margin censored data; green hatchmarks indicate positive-margin censored data. The Annals of Thoracic Surgery , 90-96DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.